Autopsy report · NCT06329570

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

“FDA reviewing”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Suspended: paused, and may or may not restart.
• 10 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 1, Phase 2

Sponsor

NaviFUS Corporation

Sponsor type

Industry

Conditions

Glioblastoma Multiforme; Glioblastoma; Glioma; Brain Tumor; Neoplasms; Neoplasms, Nerve Tissue

Interventions

NaviFUS System; Lumason; Bevacizumab

Participants

10 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• Perceval S Aortic Heart Valve Study- North America
  “FDA approval” (82% match in meaning)
• The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine
  “Pending FDA approval” (76% match in meaning)
• Electrical Impedence Tomography With ENLIGHT2100
  “Device received FDA approval” (72% match in meaning)
• Safety of SP-420 in the Treatment of Transfusional Iron Overload
  “Study is on hold by FDA in the US.” (71% match in meaning)
• MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
  “FDA hold on the project” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.